Search Results

You are looking at 1 - 10 of 378 items for :

  • "papillary thyroid carcinoma" x
  • Refine by Access: All content x
Clear All
Free access

Luca Morandi, Alberto Righi, Francesca Maletta, Paola Rucci, Fabio Pagni, Marco Gallo, Sabrina Rossi, Leonardo Caporali, Anna Sapino, Ricardo V Lloyd, and Sofia Asioli

radioiodine refractory (RAI-R) and until now no other therapeutic options have been effective ( Haugen et al . 2016 ). Recently, a new variant of papillary thyroid carcinoma (PTC), named ‘hobnail variant’ (HPTC) was described ( Motosugi et al . 2009

Open access

Adam Stenman, Samuel Backman, Klara Johansson, Johan O Paulsson, Peter Stålberg, Jan Zedenius, and C Christofer Juhlin

-cell derived neoplasia denoted as pediatric papillary thyroid carcinoma (pPTC) or pediatric follicular thyroid carcinoma, while small subsets of cases are derived from the parafollicular C-cells; namely pediatric medullary thyroid carcinoma. As in adult

Free access

Kensey Bergdorf, Donna C Ferguson, Mitra Mehrad, Kim Ely, Thomas Stricker, and Vivian L Weiss

analysis. In this Institutional Review Board approved study, files from 2008 to 2017 containing diagnoses of classical papillary thyroid carcinoma (PTC, N  = 20), follicular variant of PTC (FVTPC, N  = 12) and non-invasive follicular thyroid neoplasm with

Free access

Seo Ki Kim, Jung-Woo Woo, Jun Ho Lee, Inhye Park, Jun-Ho Choe, Jung-Han Kim, and Jee Soo Kim

Introduction Papillary thyroid carcinoma (PTC) is the most prevalent thyroid cancer and its incidence has increased rapidly worldwide ( Ahn & Park 2009 , Siegel et al. 2014 ). This increase is likely to be due to earlier detection of small

Free access

Seo Ki Kim, Jung-Woo Woo, Jun Ho Lee, Inhye Park, Jun-Ho Choe, Jung-Han Kim, and Jee Soo Kim

Introduction With a rapidly increasing incidence worldwide, papillary thyroid carcinoma (PTC) represents the majority of thyroid cancer cases ( Ahn & Park 2009 , Siegel et al . 2014 ). The recently discovered BRAF V600E mutation (hereafter

Free access

Seog Yun Park, Yuh-S Jung, Chang Hwan Ryu, Chang Yoon Lee, You Jin Lee, Eun Kyung Lee, Seok-Ki Kim, Tae Sung Kim, Tae Hyun Kim, Jeyun Jang, Daeyoon Park, Seung Myung Dong, Jae-Goo Kang, Jin Soo Lee, and Junsun Ryu

). Papillary thyroid carcinoma (PTC) comprises ∼90% of all thyroid malignancies and has an excellent prognosis with conventional therapies such as surgery and radioactive iodine therapy. Despite advances in the understanding of the underlying biological

Restricted access

Lidong Wang, Hao Tan, Yonglian Huang, Mingyue Guo, Yanxu Dong, Chenxi Liu, Huai Zhao, and Zhen Liu

Introduction Papillary thyroid carcinoma (PTC), as the most frequent histological subtype, accounts for more than 85% of thyroid cancers ( Canberk et al. 2020 ). The incidence of PTC has markedly increased over the past decades ( He et al

Free access

Brian Hung-Hin Lang, Young Jun Chai, Benjamin J Cowling, Hye Sook Min, Kyu Eun Lee, and Yeo-Kyu Youn

Introduction Papillary thyroid carcinoma (PTC) is the most common type of differentiated thyroid carcinoma with an adjusted incidence doubled over the last 20 years ( Kilfoy et al . 2009 , HKCR 2013 , SEER 2013 ). Despite its relatively good

Free access

Matthias S Dettmer, Anja Schmitt, Hans Steinert, David Capper, Holger Moch, Paul Komminoth, and Aurel Perren

all malignancies ( Schlumberger 1998 ). Papillary thyroid carcinomas (PTCs) are among the most curable cancers, and total thyroidectomy followed by adjuvant radioiodine administration cures almost all PTC patients. Patient prognosis depends on age, sex

Free access

Alfred King-yin Lam and Nassim Saremi

Introduction Cribriform-morular variant of papillary thyroid carcinoma (CMV-PTC) is an uncommon variant of papillary thyroid carcinoma. It is a variant of papillary thyroid carcinoma recognized in the current World Health Organization (WHO